Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 May 10;15:1369531. doi: 10.3389/fimmu.2024.1369531

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2024 Squicciarini, Villani, Apollonio, Fucci, Zambetti, Rossini, Pinto, Tommasi, De Roma, Strippoli and Guida

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

(A) Primary tumor histology. Hematoxilyn-eosin (H&E) staining of the primary tumor. (B) Left panel: Non-brisk T cell infiltration (anti-CD3 immunohistochemistry). Right panel: Negative tumor PD-L1 expression. Magnification 20x. (C) CT scan showing the cutaneous and subcutaneous lesions (yellow circles) before the start of the therapy (Baseline) and after 4 cycles (1st evaluation). (D) CT scan of the lung metastases (red circles) before the start of the therapy (Baseline), after 3 cycles, and after 18 cycles of immunotherapy.